Fms-like tyrosine kinase 3 (FLT3) inhibitors, which target the most commonly mutated genes in AML, and Bcl-2 inhibitors, which target a universal oncogenic signaling pathway, are the first molecular targeted drugs developed in precision medicine with respect to AML treatment [4,5], along with many other drugs. The gene discussed is BCL2; the disease is acute myeloid leukemia.